pHAGE-PIK3CA-H1047R Citations (4)

Originally described in: Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB Cancer Cell. 2018 Mar 12;33(3):450-462.e10. doi: 10.1016/j.ccell.2018.01.021. PubMed Journal

---

Articles Citing pHAGE-PIK3CA-H1047R

Articles
PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway. Zhou J, Imani S, Shasaltaneh MD, Liu S, Lu T, Fu J. Mol Biol Rep. 2022 Mar;49(3):1799-1816. doi: 10.1007/s11033-021-06990-x. Epub 2021 Nov 23. PubMed
Myoepithelial progenitors as founder cells of hyperplastic human breast lesions upon PIK3CA transformation. Goldhammer N, Kim J, Villadsen R, Ronnov-Jessen L, Petersen OW. Commun Biol. 2022 Mar 10;5(1):219. doi: 10.1038/s42003-022-03161-x. PubMed
PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor sotorasib. Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM. Br J Cancer. 2023 Jan;128(1):148-159. doi: 10.1038/s41416-022-02032-w. Epub 2022 Nov 1. PubMed
ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component. Jauhiainen S, Ilmonen H, Vuola P, Rasinkangas H, Pulkkinen HH, Keranen S, Kiema M, Liikkanen JJ, Laham-Karam N, Laidinen S, Beter M, Aavik E, Lappalainen K, Lohi J, Aronniemi J, Ord T, Kaikkonen MU, Salminen P, Tukiainen E, Yla-Herttuala S, Laakkonen JP. Elife. 2023 May 18;12:e82543. doi: 10.7554/eLife.82543. PubMed

If you have published an article using this material, please email us at to have your article added to this page.